Gil Cu, MD
Nephrology · Jacksonville, FLNPI 1558338343
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,952 of the $3,346 with a category attached, or 88.2%. It is spread thinly across 21 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $852 and has fallen 70.9% since, to $248 in 2025.
Across 138 payments — averaging $24.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$688
- Vifor Pharma, Inc.$393
- Mallinckrodt Hospital Products Inc.$333
- Amgen$314
- OPKO Pharmaceuticals, LLC$286
- Otsuka America Pharmaceutical, Inc.$273
- plus $1K from 15 others
What the payments were for
- Speaking & faculty fees$2006%
- Food & beverage$2,95288%
- Education$1946%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 27 | $688 |
| Vifor Pharma, Inc. | 7 | $393 |
| Mallinckrodt Hospital Products Inc. | 10 | $333 |
| Amgen(2 entities) | 18 | $314 |
| OPKO Pharmaceuticals, LLC | 11 | $286 |
| Otsuka America Pharmaceutical, Inc. | 18 | $273 |
| Fresenius USA Marketing, Inc. | 14 | $235 |
| Bayer | 7 | $234 |
| Mallinckrodt Enterprises LLC | 6 | $157 |
| Boston Scientific | 2 | $121 |
| Travere Therapeutics, Inc. | 8 | $102 |
| Boehringer Ingelheim | 1 | $29 |
| ANI Pharmaceuticals, Inc. | 1 | $29 |
| GSK | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Aurinia Pharma U.S., Inc. | 1 | $20 |
| Ardelyx, Inc. | 1 | $20 |
| Novo Nordisk | 1 | $18 |
| Akebia Therapeutics Inc | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,346 in reported general payments places this provider in the 70th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amlodipine Besylate | 11 | $83 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Jacksonville
- Fouad ChebibJacksonville$122K
- Jeremy CarlsonJacksonville$105K
- Craig ShapiroJacksonville$57K
- Hani WadeiJacksonville$53K
- Deborah PriceJacksonville$15K
- Tambi JarmiJacksonville$12K
- Arvind MadanOrlando$943K
- John CopleyWeston$934K
- Jorge LarranagaKissimmee$825K
- Carlos BejarFort Lauderdale$530K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.